A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity

Mickael Rosa1, Arnaud Chignon1, Zhonglin Li1

  • 11Laboratory of Cardiovascular Pathobiology, Quebec Heart and Lung Institute/Research Center, Department of Surgery, Laval University, Quebec, Canada.

NPJ Genomic Medicine
|September 26, 2019
PubMed

Insights

Reduced IL6 signaling, indicated by soluble IL6 receptor (sIL6R), may lower cardiovascular disease risk and increase longevity. However, this reduction is linked to a higher risk of atopic conditions like asthma.

Area of Science:

  • Genetics and Molecular Biology
  • Immunology
  • Cardiovascular Medicine

Background:

  • Inflammation is increasingly recognized as a key factor in the development of various cardiovascular diseases (CVDs).
  • The soluble IL6 receptor (sIL6R) acts as a negative regulator of IL6 signaling, a pathway implicated in inflammatory processes.
  • Understanding the causal relationships between sIL6R, IL6 signaling, and disease is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the causal inference between plasma levels of soluble IL6 receptor (sIL6R) and the risk of cardiovascular and immune-related disorders.
  • To explore the association of genetically determined sIL6R levels with longevity.
  • To correlate gene expression data with Mendelian randomization findings to validate IL6 signaling effects.

Main Methods:

  • Mendelian randomization (MR) analysis using multiple instrumental variables to assess causal effects of sIL6R on various diseases.
  • Analysis of associations between genetically determined sIL6R and longevity traits (parental age at death).
  • Gene-based association analysis using S-PrediXcan with GTExV7 tissue expression data.

Main Results:

  • Inverse associations were found between sIL6R and rheumatoid arthritis, atrial fibrillation, stroke, coronary artery disease, and abdominal aortic aneurysm.
  • Positive associations were observed between genetically determined sIL6R levels and atopic dermatitis and asthma.
  • sIL6R levels showed an association with increased longevity, suggesting a complex role in aging and health.

Conclusions:

  • Genetically determined reduction in IL6 signaling, mediated by sIL6R, is associated with a lower risk of multiple cardiovascular diseases and increased longevity.
  • This reduction in IL6 signaling comes at the cost of an increased risk for atopic conditions.
  • The findings highlight the dual role of IL6 signaling in cardiovascular health, longevity, and atopic disease susceptibility.